NRSN
NeuroSense Therapeutics Ltd

3,594
Mkt Cap
$25.72M
Volume
67,701.00
52W High
$2.60
52W Low
$0.6801
PE Ratio
-1.48
NRSN Fundamentals
Price
$0.866
Prev Close
$0.8542
Open
$0.855
50D MA
$0.9141
Beta
0.74
Avg. Volume
175,809.18
EPS (Annual)
-$0.5489
P/B
7.79
Rev/Employee
$0.00
$18.98
Loading...
Loading...
News
all
press releases
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS NeuroSense Announces Statistically Significant 65...
PR Newswire·17d ago
News Placeholder
More News
News Placeholder
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering...
PR Newswire·26d ago
News Placeholder
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease PR Newswire CAMBRIDGE, Mass., Jan. 21, 2026 Patent protection...
PR Newswire·2mo ago
News Placeholder
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB PR Newswire CAMBRIDGE, Mass., Jan. 8, 2026...
PR Newswire·2mo ago
News Placeholder
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study PR...
PR Newswire·3mo ago
News Placeholder
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PR Newswire CAMBRIDGE, Mass., Dec. 4, 2025 CAMBRIDGE, Mass...
PR Newswire·3mo ago
News Placeholder
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS PR Newswire CAMBRIDGE...
PR Newswire·3mo ago
<
...
1
>

Latest NRSN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.